Novo Nordisk se desploma en Bolsa ante los malos resultados de los ensayos de uno de sus fármacos contra el Alzhéimer

Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target

Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.